ShareValue.ai

ShareValue scores for CREO.LSE: Valuation 48, Quality 36, Growth 26, Health 60.

CREO.LSE
LSE

Creo Medical Group PLC

£14.50(-1.69%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

4% to 15%
Valuation
48
Fair Value
Price vs Value
Quality
36
Weak
Business Strength
Growth
26
Weak
Revenue & Earnings
Health
60
Moderate
Financial Stability
Momentum
71
Bullish
Price Trend

Company Details

About

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, it provides endotherapy accessories comprising injection needles, haemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, the company offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.

Score Analysis

AI Investment Thesis

Data as of:Jul 9, 2026
|
Last calculated:Jul 9, 2026